...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: ZHCLF

You imagine,,,,it will be 11 years since this spin off was made and 20 years for RVX....."patience",,,its well know to us all, how much shareholders of both RVX and ZENE have been forced to endure by the inexperienced management team involved in both. 

What should we sensibly wish for from these two?,,,,is all still a crap shoot in both?. No one willing to push the science onto a legit exchange. No commentary from the team as to what they anticipate will be value adding for this company. What should we be worth?,,what could we be worth,,,And if it is of any amount why are we not laying out the ground work for placing assets on any public exchange?,,is that also being directed by Pharma?,,,,Why would we sit in wait for Big Pharma to direct our path forward? Why are we not preparing for that special deal? Will we basically give our science away on each indication for a pittance as history has recorded from our pitiful ability to make deals previously? Must all still be considered a failure at this point?

Share
New Message
Please login to post a reply